Business Wire

EXPEREO

31.1.2024 09:01:28 CET | Business Wire | Press release

Share
Expereo launches Enhanced Internet, the world’s first AI driven & fully internet-based solution to improve application performance globally

Expereo, the intelligent internet company that connects people, places and things anywhere, today launched its Enhanced Internet service, the first and only AI-driven solution that continually monitors the 100,000 networks that make up the internet and predicts the best performing route for companies’ network traffic.

Empowering Cloud Performance

Despite large investments into Cloud first strategies and SaaS applications, many enterprises are still experiencing inconsistent network performance that impacts employees productivity and experience. Enhanced Internet tackles this issue by improving the consistency and quality of application performance and enables businesses to get the most from their investments in cloud and SaaS strategies.

Companies typically spend approximately €500 per employee per month on cloud based applications. Despite this investment, issues in application performance can arise when their network traffic is impacted by latency, jitter, and poor performing routes. This can have serious implications, such as a decline in employee productivity and poor user experience, which can significantly impact the company’s financial performance.

Leveraging AI and Machine Learning to Improve Efficiencies

Enhanced Internet’s AI capabilities means that customers can experience the agility and accessibility of the public internet, combined with the reliability and consistent performance levels typically expected from a private network or MPLS solution. Expereo’s proprietary AI software does this by combining AI with Machine-Learning to intelligently and proactively route network traffic over the best possible path. For customers, the knowledge extends to predictive routes for specific situation by learning the most common traffic paths for their applications and therefore being ready to predict the path before the traffic is sent.

What businesses now have at their disposal is a self-healing network that can navigate past latency and packet loss caused by network congestion.

Complete visibility from a single login.

Paired with Expereo’s customer experience platform expereoOne, businesses can have complete visibility of the health of their network and transparency showing how Enhanced Internet has improved their application performance all from a single login. In addition to performance data, incident management, order status and invoices at site level, expereoOne displays latency and packet loss statistics, percentage of times routes have been changed and overall quality of service statistics personalized by Top 5 cloud destinations for their business. Complete visibility of how application performance has been improved by Enhanced Internet.

Sander Barens, Chief Product Officer for Expereo, commented: “Unpredictable network performance may not seem, at first, like an urgent threat to your business’ success. That is until you realize the increase demands and pressure it puts on IT teams, the damaging impact it has on business efficiency and hours of productivity downtime. With Cloud applications now laying the groundwork for so many modern businesses, connecting to the public internet with the best possible application user experience is the next logical step for global businesses looking to future proof their operations.

“At Expereo, we’re already using our latest AI solution, Enhanced Internet, to lift several customers into the internet age of enhanced connectivity, with very positive results and have big plans to elevate even more global enterprises into this new era of AI internet connectivity over the coming year.”

Find out more here: Enhanced Internet (expereo.com)

About Expereo

Expereo is the intelligent internet company that connects people, places and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to 600,000 locations worldwide, working with over 4,000 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility and value of the Internet, with optimal network performance.

Expereo was acquired in Feb 2021, by Vitruvian Partners. The international growth capital and buyout firm, acquired a majority shareholding from leading European private equity firm, Seven2.

www.expereo.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131147075/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye